Filtern
Gehört zur Bibliographie
- ja (813)
Erscheinungsjahr
Dokumenttyp
- Dissertation (803)
- Artikel / Aufsatz in einer Zeitschrift (9)
- Buch (1)
Sprache
- Englisch (813) (entfernen)
Schlagworte
- Maus (32)
- Thrombozyt (31)
- Taufliege (20)
- Tissue Engineering (19)
- Genexpression (16)
- T-Lymphozyt (15)
- Dendritische Zelle (14)
- Biene (13)
- Entzündung (13)
- Angst (12)
Institut
- Graduate School of Life Sciences (813) (entfernen)
Sonstige beteiligte Institutionen
- Helmholtz Institute for RNA-based Infection Research (HIRI) (8)
- Rudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg (2)
- Universitätsklinikum Münster (2)
- Zentrum für Infektionsforschung (ZINF) Würzburg (2)
- Bio-Imaging Center Würzburg (1)
- Biomedical Center Munich, Department of Physiological Chemistry, Ludwig-Maximilians-Universität München (1)
- CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - the development agency of the Brazilian Federal Government (1)
- Carl-Ludwig-Institut für Physiologie, Universität Leipzig (1)
- Chair of Experimental Biomedicine I (1)
- DAAD - Deutscher Akademischer Austauschdienst (1)
The majority of rapid cell-to-cell communication mechanisms and information processing within the nervous system makes use of chemical synapses. Fast neurotransmission on these sites not only requires very close apposition of pre- and postsynaptic partners, but also depends on an effective structural arrangement of cellular components on both sides of the synaptic cleft. Synaptic vesicles fuse at active zones (AZs), characterized by an electron-dense protein mesh of insufficiently characterized composition and function. EM analysis of synapses identified electron dense structures thought (but not proven) to play an important role for vesicle release efficacy. The molecular organization of presynaptic AZs during Ca2+ influx–triggered neurotransmitter release is currently a focus of intense investigation. Due to its appearance in electron micrographs, dense bodies at Drosophila synapses were named T-bars. Together with the lab of Erich Buchner, we recently showed that Bruchpilot (BRP) of the Drosophila melanogaster, homologous to the mammalian CAST/ERC family in its N-terminal half, is essential for the T-bar assembly at AZs and efficient neurotransmitter release respectively. The question, in which way BRP contributes to functional and structural organization of the AZ, was a major focus of this thesis. First, stimulated emission depletion microscopy (STED), featuring significantly increased optical resolution, was used to achieve first insights into ‘cytoarchitecture’ of the AZ compartment. In addition, in vivo live imaging experiments following identified populations of synapses over extended periods were preformed to address the trafficking of protein at forming synapses and thereby providing a temporal sequence for the AZ assembly process. Apart from BRP, two additional AZ proteins, DLiprin-α and DSyd-1, were included into the analysis, which were both shown to contribute to efficient AZ assembly. Drosophila Syd-1 (DSyd-1) and Drosophila Liprin-α (DLiprin-α) clusters initiated AZ assembly, finally forming discrete ‘quanta’ at the AZ edge. ELKS-related Bruchpilot, in contrast, accumulated late from diffuse pools in the AZ center, where it contributed to the electron dense specialization by adopting an extended conformation vertical to the AZ membrane. We show that DSyd-1 and DLiprin-α are important for efficient AZ formation. The results of this thesis describe AZ assembly as a sequential protracted process, with matured AZs characterized by sub-compartments and likely quantal building blocks. This step-wise, in parts reversible path leading to mature AZ structure and function offers new control possibilities in the development and plasticity of synaptic circuits.
Marine sponges (Porifera) harbor diverse microbial communities within their mesohyl, among them representatives of the phylum Actinobacteria, commonly known as actinomycetes. Actinomycetes are prolific producers of pharmacologically important compounds and are responsible for producing the majority of antibiotics. The main aim of this Ph.D. study was to investigate the metabolic potential of the sponge-associated actinomycetes to produce novel anti-infective agents. The first aim was to cultivate actinomycetes derived from different marine sponges. 16S rDNA sequencing revealed that the strains belonged to diverse actinomycete genera such as Gordonia, Isoptericola, Micromonospora, Nocardiopsis, Saccharopolyspora and Streptomyces. Phylogenetic analyses and polyphasic characterization further revealed that two of these strains represent new species, namely Saccharopolyspora cebuensis strain SPE 10-1T (Pimentel-Elardo et al. 2008a) and Streptomyces axinellae strain Pol001T (Pimentel-Elardo et al. 2008b). Furthermore, secondary metabolite production of the actinomycete strains was investigated. The metabolites were isolated using a bioassay-guided purification scheme followed by structure elucidation using spectroscopic methods and subjected to an elaborate anti-infective screening panel. Several interesting compounds were isolated namely, the novel polyketides cebulactam A1 and A2 (Pimentel-Elardo et al. 2008c), a family of tetromycin compounds including novel derivatives, cyclodepsipeptide valinomycin, indolocarbazole staurosporine, diketopiperazine cycloisoleucylprolyl and butenolide. These compounds exhibited significant anti-parasitic as well as protease inhibitory activities. The third aim of this Ph.D. study was to identify biosynthetic gene clusters encoding for nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) present in the actinomycete strains. Genomic library construction and sequencing revealed insights into the metabolic potential and biosynthetic pathways of selected strains. An interesting NRPS system detected in Streptomyces sp. strain Aer003 was found to be widely distributed in several sponge species, in an ascidian and in seawater and is postulated to encode for a large peptide molecule. Sequencing of the PKS gene cluster of Saccharopolyspora cebuensis strain SPE 10-1T allowed the prediction of the cebulactam biosynthetic pathway which utilizes 3-amino-5-hydroxybenzoic acid as the starter unit followed by successive condensation steps involving methylmalonyl extender units and auxiliary domains responsible for the polyketide assembly. In conclusion, this Ph.D. study has shown that diverse actinomycete genera are associated with marine sponges. The strains, two of them novel species, produced diverse chemical structures with interesting anti-infective properties. Lastly, the presence of biosynthetic gene clusters identified in this study substantiates the biosynthetic potential of actinomycetes to produce exploitable natural products and hopefully provides a sustainable supply of anti-infective compounds.
The yeast Candida albicans is a member of the normal microflora on the mucosal surfaces of the gastrointestinal and urogenital tract in healthy persons. However, it is an opportunistic pathogen that can cause a range of infections from superficial to disseminated, in response to perturbation of the normal microflora or alterations in the host immunity. C. albicans exhibits a variety of characteristics such as adhesion, morphogenetic switching and secreted aspartic protease production that contribute to its virulence. Expression of many of these virulence factors is controlled by the availability of essential element, nitrogen. C. albicans undergoes morphogenetic transition to form filaments under nitrogen starvation conditions and this switch is controlled by the ammonium permease Mep2p. However, little is known about how this signaling function of Mep2p is regulated. Mutational analysis of Mep2p was carried out to identify the residues that confer signaling activity to this permease. The C-terminal cytoplasmic tail of Mep2p contains a signaling domain that is dispensable for ammonium transport but essential for the signaling activity of Mep2p. In this work, progressive C-terminal truncations analysis demonstrated that a MEP2DC433 allele was still able to induce filamentation while nitrogen starvation-induced filamentous growth was abolished in cells expressing a MEP2DC432 allele. Therefore, tyrosine at position 433 (Y433) is the last amino acid in Mep2p that is essential for signaling. To gain insights into how the signaling activity of Mep2p is regulated by ammonium availability and transport, conserved residues that have been implicated in ammonium binding or uptake were mutated. Mutation of D180, which has been proposed to mediate initial contact with extracellular ammonium, or the pore-lining residues H188 and H342 abolished Mep2p expression, indicating that these residues are important for protein stability. Mutation of F239, which together with F126 is predicted to form an extracytosolic gate to the conductance channel, abolished both ammonium uptake and Mep2p-dependent filamentation, despite proper localization of the protein. On the other hand, mutation of W167, which is assumed to participate along with Y122, F126, and S243 in the recruitment and coordination of the ammonium ion at the extracytosolic side of the cell membrane, also abolished filamentation without having a strong impact on ammonium transport, demonstrating that extracellular alterations in Mep2p can affect intracellular signaling. Mutation of Y122 reduced ammonium uptake much more strongly than mutation of W167 but still allowed efficient filamentation, indicating that the signaling activity of Mep2p is not directly correlated with its transport activity. An important aspect in the ability of Mep2p to stimulate filamentation in response to nitrogen limitation is its high expression levels. The cis-acting sequences and trans-acting regulators that mediate MEP2 induction in response to nitrogen limitation were identified. Promoter analysis revealed that two putative binding sites for GATA transcription factors have a central role in MEP2 expression, as deletion of the region containing these sites or mutation of the GATAA sequences in the full-length MEP2 promoter strongly reduced MEP2 expression. To elucidate the roles of the GATA transcription factors GLN3 and GAT1 in regulating MEP2 expression, mutants lacking one or both of these transcription factors were constructed. Mep2p expression was strongly reduced in gln3D and gat1D single mutants and virtually abolished in gln3D gat1D double mutants. Deletion of GLN3 strongly inhibited filamentous growth under limiting nitrogen conditions, which could be rescued by constitutive expression of MEP2 from the ADH1 promoter. In contrast, inactivation of GAT1 had no effect on filamentation. Surprisingly, filamentation became partially independent of the presence of a functional MEP2 gene in the gat1D mutants, indicating that the loss of GAT1 function results in the activation of other pathways that induce filamentous growth. These findings demonstrated that the GATA transcription factors Gln3p and Gat1p control expression of the MEP2 ammonium permease and that GLN3 is also an important regulator of nitrogen starvation-induced filamentous growth in C. albicans. C. albicans mutants lacking both the GATA transcription factors Gln3p and Gat1p were unable to grow in a medium containing an alternative nitrogen source, bovine serum albumin (BSA) as the sole nitrogen source. The ability to utilize proteins as sole source of nitrogen for growth of C. albicans is conferred by the secreted aspartic protease Sap2p, which degrades the proteins, and oligopeptide transporters that mediate uptake of the proteolytic products into cell. The growth defect of gln3D gat1D mutants was mainly caused by their inability to express the SAP2 gene, as SAP2 expression from the constitutive ADH1 promoter restored the ability of the mutants to grow on BSA. Expression of STP1, which encodes a transcription factor that is required for SAP2 induction in the presence of proteins, was regulated by Gln3p and Gat1p. Forced expression of STP1 from a tetracycline-inducible promoter bypassed the requirement of the GATA transcription factors for growth of C. albicans on proteins. When preferred nitrogen sources are available, SAP2 is repressed and this nitrogen catabolite repression of SAP2 was correlated with downregulation of STP1 under these conditions. Tetracycline-induced STP1 expression abolished nitrogen catabolite repression of SAP2, demonstrating that regulation of STP1 expression levels by the GATA transcription factors is a key aspect of both positive and negative regulation of SAP2 expression. Therefore, by using a regulatory cascade in which expression of the specific transcription factor Stp1p is controlled by the general regulators Gln3p and Gat1p, C. albicans places SAP2 expression under nitrogen control and ensures proper expression of this virulence determinant. In summary, the present study illustrated how GATA factors, Gln3p and Gat1p, play partially overlapping, but distinct roles, in mediating the appropriate responses of C. albicans to the availability of different nitrogen sources. These responses are also determinants of pathogenicity of the fungus. The relative contributions of Gln3p and Gat1p vary with their target genes and the availability of nitrogen source. Overall, these findings provide us with a better understanding of the molecular basis of some of the important processes that help in adaptation of C. albicans to various environmental conditions. The yeast Candida albicans is a member of the normal microflora on the mucosal surfaces of the gastrointestinal and urogenital tract in healthy persons. However, it is an opportunistic pathogen that can cause a range of infections from superficial to disseminated, in response to perturbation of the normal microflora or alterations in the host immunity. C. albicans exhibits a variety of characteristics such as adhesion, morphogenetic switching and secreted aspartic protease production that contribute to its virulence. Expression of many of these virulence factors is controlled by the availability of essential element, nitrogen. C. albicans undergoes morphogenetic transition to form filaments under nitrogen starvation conditions and this switch is controlled by the ammonium permease Mep2p. However, little is known about how this signaling function of Mep2p is regulated. Mutational analysis of Mep2p was carried out to identify the residues that confer signaling activity to this permease. The C-terminal cytoplasmic tail of Mep2p contains a signaling domain that is dispensable for ammonium transport but essential for the signaling activity of Mep2p. In this work, progressive C-terminal truncations analysis demonstrated that a MEP2DC433 allele was still able to induce filamentation while nitrogen starvation-induced filamentous growth was abolished in cells expressing a MEP2DC432 allele. Therefore, tyrosine at position 433 (Y433) is the last amino acid in Mep2p that is essential for signaling. To gain insights into how the signaling activity of Mep2p is regulated by ammonium availability and transport, conserved residues that have been implicated in ammonium binding or uptake were mutated. Mutation of D180, which has been proposed to mediate initial contact with extracellular ammonium, or the pore-lining residues H188 and H342 abolished Mep2p expression, indicating that these residues are important for protein stability. Mutation of F239, which together with F126 is predicted to form an extracytosolic gate to the conductance channel, abolished both ammonium uptake and Mep2p-dependent filamentation, despite proper localization of the protein. On the other hand, mutation of W167, which is assumed to participate along with Y122, F126, and S243 in the recruitment and coordination of the ammonium ion at the extracytosolic side of the cell membrane, also abolished filamentation without having a strong impact on ammonium transport, demonstrating that extracellular alterations in Mep2p can affect intracellular signaling. Mutation of Y122 reduced ammonium uptake much more strongly than mutation of W167 but still allowed efficient filamentation, indicating that the signaling activity of Mep2p is not directly correlated with its transport activity. An important aspect in the ability of Mep2p to stimulate filamentation in response to nitrogen limitation is its high expression levels. The cis-acting sequences and trans-acting regulators that mediate MEP2 induction in response to nitrogen limitation were identified. Promoter analysis revealed that two putative binding sites for GATA transcription factors have a central role in MEP2 expression, as deletion of the region containing these sites or mutation of the GATAA sequences in the full-length MEP2 promoter strongly reduced MEP2 expression. To elucidate the roles of the GATA transcription factors GLN3 and GAT1 in regulating MEP2 expression, mutants lacking one or both of these transcription factors were constructed. Mep2p expression was strongly reduced in gln3D and gat1D single mutants and virtually abolished in gln3D gat1D double mutants. Deletion of GLN3 strongly inhibited filamentous growth under limiting nitrogen conditions, which could be rescued by constitutive expression of MEP2 from the ADH1 promoter. In contrast, inactivation of GAT1 had no effect on filamentation. Surprisingly, filamentation became partially independent of the presence of a functional MEP2 gene in the gat1D mutants, indicating that the loss of GAT1 function results in the activation of other pathways that induce filamentous growth. These findings demonstrated that the GATA transcription factors Gln3p and Gat1p control expression of the MEP2 ammonium permease and that GLN3 is also an important regulator of nitrogen starvation-induced filamentous growth in C. albicans. C. albicans mutants lacking both the GATA transcription factors Gln3p and Gat1p were unable to grow in a medium containing an alternative nitrogen source, bovine serum albumin (BSA) as the sole nitrogen source. The ability to utilize proteins as sole source of nitrogen for growth of C. albicans is conferred by the secreted aspartic protease Sap2p, which degrades the proteins, and oligopeptide transporters that mediate uptake of the proteolytic products into cell. The growth defect of gln3D gat1D mutants was mainly caused by their inability to express the SAP2 gene, as SAP2 expression from the constitutive ADH1 promoter restored the ability of the mutants to grow on BSA. Expression of STP1, which encodes a transcription factor that is required for SAP2 induction in the presence of proteins, was regulated by Gln3p and Gat1p. Forced expression of STP1 from a tetracycline-inducible promoter bypassed the requirement of the GATA transcription factors for growth of C. albicans on proteins. When preferred nitrogen sources are available, SAP2 is repressed and this nitrogen catabolite repression of SAP2 was correlated with downregulation of STP1 under these conditions. Tetracycline-induced STP1 expression abolished nitrogen catabolite repression of SAP2, demonstrating that regulation of STP1 expression levels by the GATA transcription factors is a key aspect of both positive and negative regulation of SAP2 expression. Therefore, by using a regulatory cascade in which expression of the specific transcription factor Stp1p is controlled by the general regulators Gln3p and Gat1p, C. albicans places SAP2 expression under nitrogen control and ensures proper expression of this virulence determinant. In summary, the present study illustrated how GATA factors, Gln3p and Gat1p, play partially overlapping, but distinct roles, in mediating the appropriate responses of C. albicans to the availability of different nitrogen sources. These responses are also determinants of pathogenicity of the fungus. The relative contributions of Gln3p and Gat1p vary with their target genes and the availability of nitrogen source. Overall, these findings provide us with a better understanding of the molecular basis of some of the important processes that help in adaptation of C. albicans to various environmental conditions.
Cancer immune therapy represents a promising alternative to conventional anti tumour therapy like radiation, surgical excision of the tumour or classical chemotherapy. The biggest advantage of cancer immune therapy is specificity, achieved by targeting tumour-associated antigens with the effector arms of the host immune system. This is believed to result in less adverse effects than standard therapy and reaches presumably also metastatic lesions at distant sites from the primary tumour. However, cancer immune therapy by vaccination against tumour antigens failed to translate into clinical success, yet. Furthermore, despite tremendous clinical efforts malignant disease still results in high mortalities giving rise to the need for novel vaccination-based therapies against cancer. An interesting approach in this respect is the use of bacteria like attenuated salmonellae as carriers for heterologous cancer antigens. In numerous preclinical studies Salmonella-based vaccines could elicit cell mediated immune responses of the CD4+ and CD8+ type against own and heterologous antigens which make them ideally suited for anti tumour therapy. Special delivery systems in Salmonella carriers like surface display or secretion of antigens were shown to be advantageous for the immunological outcome. This work focussed on developing novel Salmonella carriers for immune therapy against cancer. In a first project, TolC, a multifunctional outer membrane protein of E. coli was utilized as membrane anchor for 3 heterologous antigens. Respective TolC fusion proteins encoded on plasmids were analysed for expression, functionality and plasmid stability in different engineered Salmonella strains. The amount of membrane localized recombinant TolC was enhanced in tolC-deficient strains. Furthermore, fusion proteins were functional and plasmid stability was very high in vitro and in vivo. Disappointingly, neither specific CD4+/CD8+ T-cell responses against the model antigen ovalbumin nor CD8+ responses against the cancer antigen BRAFV600E were detectable in murine model systems. However, mice immunized with Salmonella strains displaying an immunodominant epitope of the cancer related prostate specific antigen (PSA) were partially protected from subsequent tumour challenge with a PSA expressing melanoma cell line. Tumour growth in mice immunized with the respective strain was significantly decelerated compared to controls, thus indicating that this surface display system confers protective immunity against tumours. In a second study, the approved typhoid vaccine strain Salmonella enterica serovar Typhi Ty21a (Ty21a) was improved for the hemolysin type I secretion system of E. coli. This secretion system is widely used for heterologous antigen delivery in live bacterial vaccines. It was demonstrated throughout this work that a mutation of rpoS in Ty21a correlated with decreased ability for hemolysin secretion compared to other Salmonella strains. Complementation with rpoS or the presumed downstream target of rpoS, rfaH resulted in enhanced expression and secretion of heterologous hemolysin in Ty21a. Presumably by raising the amount of free antigen, rfaHcomplemented Ty21a elicited higher antibody titres against heterologous hemolysin in immunized mice than controls and even rpoS-positive Ty21a. Therefore, rfaHcomplemented Ty21a could form the basis of a novel generation of vaccines for human use based on (cancer) antigen secretion.
Echinococcus multilocularis is the causative agent of alveolar echinococcosis (AE), a life-threatening disease with limited options of chemotherapeutic treatment. Anti-AE chemotherapy is currently based on a single class of drugs, the benzimidazoles. Although acting parasitocidic in vitro, benzimidazoles are merely parasitostatic during in vivo treatment of AE and cause severe site effects. In the case of operable lesions, the resection of parasite tissue needs to be supported by a prolonged chemotherapy. Thus, the current treatment options for AE are inadequate and require alternatives. In the present work, the flatworm signaling pathways were analyzed to establish potential targets for novel therapeutic approaches. I focused on factors that are involved in development and proliferation of E. multilocularis using molecular, biochemical and cell biological methods. Among the analysed factors were three MAP kinases of the parasite, EmMPK1, an Erk-1/2 orthologue, EmMPK2, a p38 orthologue and EmMPK3, an Erk7/8 orthologue. Further, I identified and characterized EmMKK2, a MEK1/2 orthologue of the parasite, which, together with the known kinases EmRaf and EmMPK1, forms an Erk1/2-like MAPK module. Moreover, I was able to demonstrate several influences of host growth factors such as EGF (epidermal growth factor) and insulin on worm signaling mechanisms and larval growth, including the phosphorylation of Elp, an ezrin-radixin-moesin like protein, EmMPK1, EmMPK3 and increased mitotic activity of Echinococcus cells. In addition, several substances were examined for their efficacy against the parasite including (i) general tyrosine kinase inhibitors (PP2, leflunamide), (ii) compounds designed to inhibit the activity of receptor tyrosine kinases, (iii) anti-neoplastic agents (miltefosine, perifosine), (iv) serine/threonine kinase inhibitors that have been designed to block the Erk1/2 MAPK cascade and (v) inhibitors of p38 MAPKs. In these studies, EmMPK2 proved to be a promising drug target for the following reasons. Amino acid sequence analysis disclosed several differences to human p38 MAPKs, which is likely to be the reason for the observed enhanced basal activity of recombinant EmMPK2 towards myelin basic protein in comparison to human recombinant p38 MAPK-α. In addition, the prominent auto-phosphorylation activity of the recombinant EmMPK2 protein together with the absence of an interaction with the Echinococcus MKKs suggest a different mechanism of regulation compared to the human enzyme. EmMPK2 activity could be effectively inhibited in vitro and in cultivated metacestode vesicles by treatment with SB202190 and ML3403, two ATP-competitive pyridinyl imidazole inhibitors of p38 MAPKs, in a concentration-dependent manner. Moreover, both compounds, in particular ML3403, caused parasite vesicle inactivation at concentrations which did not affect cultured mammalian cells. Likewise, during the cultivation of Echinococcus primary cells, the presence of ML3403 prevented the generation of new vesicles. Targeting members of the EGF signaling pathway, particulary of the Erk1/2-like MAPK cascade, with Raf and MEK inhibitors prevented the phosphorylation of EmMPK1 in metacestodes cultivated in vitro. However, although parasite growth was prevented under these conditions, the structural integrity of the metacestode vesicles maintained during long-term cultivation in the presence of the MAPK cascade inhibitors. Similar results were obtained when studying the effects of other drugs mentioned above. Taken together, several targets could be identified that reacted with high sensitivity to the presence of inhibitory substances, but did not cause the parasite’s death with one exception, the pyridinyl imidazoles. Based on the presented data, I suggest pyridinyl imidazoles as a novel class of anti-Echinococcus drugs and imply EmMPK2 as survival signal mediating factor, the inhibition of which could be used for the treatment of AE.
The proteins of the RAF family (A-RAF, B-RAF, and C-RAF) are serine/threonine-kinases that play important roles in development, mature cell regulation and cancer. Although it is widely held that their localization on membranes is an important aspect of their function, there are few data addressing this aspect of their mode of action. Here, we report that each member of the RAF family exhibits a specific distribution at the level of cellular membranes, and that C-RAF is the only isoform that directly targets mitochondria. We find that the RAF kinases exhibit intrinsic differences in terms of mitochondrial affinity, and that C-RAF is the only isoform that binds this organelle efficiently. This affinity is conferred by the C-RAF amino-terminal domain, and does not depend on the presence of RAS GTPases on the surface of mitochondria. Furthermore, we analyze the consequences of C-RAF activation on the cellular and molecular level. C-RAF activation on mitochondria dramatically changes their morphology and their subcellular distribution. On the molecular level, we examine the role of C-RAF in the regulation of the pro-apoptotic Bcl-2 family member BAD. This protein exhibits the original mode of regulation by phosphorylation. Although several reports addressed the regulation of BAD by C-RAF, the exact mode of action as well as the consequences of C-RAF activation on BAD are still not completely understood. We show that the inducible activation of C-RAF promotes the rapid phosphorylation of BAD on Serine-112 (Ser-75 in the human protein), through a cascade involving the kinases MEK and RSK. Our findings reveal a new aspect of the regulation of BAD protein and its control by the RAF pathway: we find that C-RAF activation promotes BAD poly-ubiquitylation in a phosphorylation-dependent fashion, and increases the turn-over of this protein through proteasomal degradation.
Platelet activation induces cytoskeletal rearrangements involving a change from discoid to spheric shape, secretion, and eventually adhesion and spreading on immobilized ligands. Small GTPases of the Rho family, such as Rac1 and Cdc42, are known to be involved in these processes by facilitating the formation of lamellipodia and filopodia, respectively. This thesis focuses on the role Rac1 and Cdc42 for platelet function and formation from their precursor cells, the megakaryocytes (MKs), using conditional knock-out mice. In the first part of the work, the involvement of Rac1 in the activation of the enzyme phospholipase (PL) C2 in the signaling pathway of the major platelet collagen receptor glycoprotein (GP) VI was investigated. It was found that Rac1 is essential for PLC2 activation independently of tyrosine phosphorylation of the enzyme, resulting in a specific platelet activation defect downstream of GPVI, whereas signaling of other activating receptors remains unaffected. Since Rac1-deficient mice were protected from arterial thrombosis in two different in vivo models, the GTPase might serve as a potential target for the development of new drugs for the treatment and prophylaxis of cardio- and cerebrovascular diseases. The second part of the thesis deals with the first characterization of MK- and platelet-specific Cdc42 knock-out mice. Cdc42-deficient mice displayed mild thrombo-cytopenia and platelet production from mutant MKs was markedly reduced. Unexpectedly, Cdc42-deficient platelets showed increased granule content and release upon activation, leading to accelerated thrombus formation in vitro and in vivo. Furthermore, Cdc42 was not generally required for filopodia formation upon platelet activation. Thus, these results indicate that Cdc42, unlike Rac1, is involved in multiple signaling pathways essential for proper platelet formation and function. Finally, the outcome of combined deletion of Rac1 and Cdc42 was studied. In contrast to single deficiency of either GTPase, platelet production from double-deficient MKs was virtually abrogated, resulting in dramatic macrothrombocytopenia in the animals. Formed platelets were largely non-functional leading to a severe hemostatic defect and defective thrombus formation in double-deficient mice in vivo. These results demonstrate for the first time a functional redundancy of Rac1 and Cdc42 in the hematopoietic system.
Diverse roles of B cells in the pathophysiology of rheumatoid arthritis are now well established. B cells contribute to autoimmunity by producing autoantibodies, processing autoantigen and the production of different cytokines which are involved in the inflammatory cascade. Therefore approaches to target B lymphocytes directly or indirectly are developed for clinical practice to treat autoimmune diseases including rheumatoid arthritis. Transient B cell depletion by rituximab (anti-CD20 antibody) has gained prime importance in recent years. Meanwhile anti-CD20 mediated transient B cell depletion therapy is now used with clinical efficiency in the treatment of patients with rheumatoid arthritis. Rituximab induces noteworthy changes in the homeostasis of peripheral B cell subpopulations during the repletion phase with emerging immature B cells in peripheral blood followed by normalization of the naïve B cell pool and a longterm delay in memory B cell subsets in patients with rheumatoid arthritis. Particularly IgD+CD27+ memory B cells repopulate very slowly during B cell regeneration. In a prospective clinical study, our laboratory has shown that the overall number of memory B cells correlates well to the duration of clinical response to rituximab. Little is known about the particular molecular changes in the memory B cell repertoire after rituximab therapy. To better understand peripheral memory B cell subsets, we explored in detail the somatic mutational frequency and pattern of Ig-VH3 gene rearrangements by using a single B cell sorting technique followed by nested PCR before and up to 6 years after rituximab therapy in 18 RA patients. We compared rituximab inflicted dynamics of mutational acquisition to memory B cell repopulation in 4 healthy donors and 6 non RA patients undergoing high dose chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT). Firstly we analyzed the peripheral composition of memory B cell subsets. The phenotypic analysis of peripheral pre-switch (IgD+CD27+) and post-switch (IgD-CD27+) memory B cells did not reveal any quantitative differences in RA patients prior to B cell depletion therapy compared to healthy donors. However extending those studies in directly analysing the B cell immunoglobulin receptor from individual B cells of RA patients and healthy controls brought interesting results. Pre-switched and post-switched memory B cells showed a highly significant difference in the amount of mutations/sequence. The population of IgD+CD27+ memory B cells is comprised of non-mutated, low and highly mutated (median= 9 mutations/ sequence) rearranged Ig receptors whereas the IgD-CD27+ memory B cell compartment shows quite uniformly highly mutated (median 18 mutations/ sequence) sequences indicating a significant difference between these two groups (mutational frequencies 3.83±0.19% vs. 7.1±0.53%; P=0.0001). Profound changes were noted in the re-emerging pre-switch memory B cells (IgD+/ CD27+) after transient B cell depletion with rituximab. These cells showed over a time period of 6 years after treatment with rituximab significantly delayed acquisition of mutations in Ig receptors on the single B cell level. One year after a single course of rituximab 84% of single repopulating IgD+/CD27+ B cells were unmutated and no highly mutated Ig-VH gene rearrangements were found(P=0.0001). Over time increasing numbers of mutations could be detected i-e 7.8% during 2nd year of regeneration (P=0.0001), 14% after 4 years (n=2). Nevertheless even 6 years after rituximab, VH mutations in IgD+ memory B cells were still reduced with 27% highly mutated sequences compared to 52% pre therapy(P=0.0001). Post-therapy analysis of CDR3 length of regenerated IgD+ memory B cells revealed increased CDR3 length which also correlates well with elevated number of non-mutated VH gene rearrangements observed during repletion phase. In comparison patients undergoing high dose chemotherapy followed by allogeneic stem cell transplantation repopulated IgD+ memory cells earlier with higher numbers of mutations in IgD+ memory B cells. One year after transplantation Ig receptors showed already 22% highly mutated and 42 % unmutated VH rearrangements. These findings indicated that anti-CD20 mediated B cell depletion seems not only to delay the production of pre-switch memory B cells but also significantly affects the acquisition of mutations in the IgD+ memory B cell pool. In contrary to the mutational pattern of IgD+ memory B cells after rituximab class switched memory B cells repopulate in the periphery with quantitatively normal mutations in their Ig receptors. Although the numeric replenishment of these recirculating class-switched memory B cells was also reduced after rituximab, we found no delay in quantitative acquisition of mutations also an increased proportion of IgA expressing B cells in this memory B cell subset was detected. Our data showed that post-therapy mutational targeting in RGYW/WRCY motifs were significantly increased as compared with that of pre-treatment (27% before rituximab vs. 43% after therapy, P=0.0003) indicating that affinity maturation may operate differently in class-switched memory B cells before and after B cell depletion. These results indicate a normal development process with an unimpaired mechanism of mutational acquisition in class-switched memory B cells. These data argue for different requirements to undergo somatic hypermutations in IgD+ memory B cells in comparison to class switched memory B cells. To conclude, our work has demonstrated for the first time a delayed acquisition of somatic hypermutations at single Ig receptor VH gene rearrangements of IgD+ memory B cells in comparison to class-switched memory B cells. These results demonstrate that IgD+ memory B cells are particularly susceptible to anti-CD20 treatment in patients with rheumatoid arthritis. In addition antigenic pressure and/or selection are substantially reduced by rituximab therapy which is basically not seen in the class-switched memory compartment. These data are in line with the hypothesis that IgD+ memory B cells have distinct requirements for activating their mutational machinery compared to class-switched memory B cells which recover normal mutations during regeneration phase. The results have implications in understanding the pathophysiology of memory B cell in rheumatoid arthritis and may be helpful in designing new targeted therapies.
An increase in cytosolic Ca2+ levels ([Ca2+]i) is a key event that occurs downstream of many signaling cascades in response to an external stimulus and regulates a wide range of cellular processes, including platelet activation. Eukaryotic cells increase their basal [Ca2+]i allowing extracellular Ca2+ influx into the cell, which involves different mechanisms. Store-operated Ca2+ entry (SOCE) is considered the main mechanism of extracellular Ca2+ influx in electrically non-excitable cells and platelets, and comprises an initial Ca2+ depletion from intracellular Ca2+ stores prior to activation of extracellular Ca2+ influx. Although the close relation between Ca2+ release from intracellular stores and extracellular Ca2+ influx was clear, the nature of the signal that linked both events remained elusive until 2005, when Stromal Interaction Molecule 1 (STIM1) was identified as an endoplasmic reticulum (ER) Ca2+ sensor essential for inositol (1,4,5)-trisphosphate (IP3)-mediated SOCE in vitro. However, the function of its homologue STIM2 in Ca2+ homeostasis was in general unknown. Therefore, mice lacking STIM2 (Stim2-/-) were generated in this work to study initially STIM2 function in platelets and in cells of the immune system. Stim2-/- mice developed normally in size and weight to adulthood and were fertile. However, for unknown reasons, they started to die spontaneously at the age of 8 weeks. Unexpectedly, Stim2-/- mice did not show relevant differences in platelets, revealing that STIM2 function is not essential in these cells. However, STIM2 seems to be involved in mammary gland development during pregnancy and is essential for mammary gland function during lactation. CD4+ T cells lacking STIM2 showed decreased SOCE. Our data suggest that STIM2 has a very specific function in the immune system and is involved in Experimental Autoimmune Encephalomyelitis (EAE) at early stages of the disease progression. Stim2-/- neurons were also defective in SOCE. Surprisingly, our results evidenced that STIM2 participates in mechanisms of neuronal damage after ischemic events in brain. This is the first time that the involvement of SOCE in ischemic neuronal damage has been reported. This finding may serve as a basis for the development of novel neuroprotective agents for the treatment of ischemic stroke, and possibly other neurodegenerative disorders in which disturbances in cellular Ca2+ homeostasis are considered a major pathophysiological component.
Extracellular signals are translated and amplified via cascades of serially switched protein kinases, MAP kinases (MAPKs). One of the MAP pathways, the classical RAS/RAF/MEK/ERK pathway, transduces signals from receptor tyrosine kinases and plays a central role in regulation of cell proliferation. RAF kinases (A-, B- and C-RAF) function atop of this cascade and convert signals emanating from conformational change of RAS GTPases into their kinase activity, which in turn phosphorylates their immediate substrate, MEK. Disregulated kinase activity of RAF can result in tumor formation, as documented for many types of cancer, predominantly melanomas and thyroid carcinomas (B-RAF). A-RAF is the least characterized RAF, possibly due to its low intrinsic kinase activity and comparatively mild phenotype of A-RAF knockout mice. Nevertheless, the unique phenotype of araf -/- mice, showed predominantly neurological abnormalities such as cerebellum disorders, suggesting that A-RAF participates in a specific process not complemented by activities of B- and CRAF. Here we describe the role of A-RAF in membrane trafficking and identify its function in a specific step of endocytosis. This work led to the discovery of a C-terminally truncated version of A-RAF, AR149 that strongly interfered with cell growth and polarization in yeast and with endocytosis and actin polymerization in mammalian cells. As this work was in progress two splicing isoforms of ARAF, termed DA-RAF1 and DA-RAF2 were described that act as natural inhibitors of RAS-ERK signaling during myogenic differentiation (Yokoyama et al., 2007). DA-RAF2 contains the first 153 aa of A-RAF and thus is nearly identical with AR149. AR149 localized specifically to the recycling endosomal compartments as confirmed by colocalization and coimmunoprecipitation with ARF6. Expression of AR149 interferes with recycling of endocytosed transferrin (Tfn) and with actin polymerization. The endocytic compartment, where internalized Tfn is trapped, was identified as ARF6- and RAB11- positive endocytic vesicles. We conclude that the inhibition of Tfn trafficking in the absence of A-RAF or under overexpression of AR149 occurs between tubular- and TGNassociated recycling endosomal compartments. siRNA-mediated depletion of endogenous A-RAF or inhibition of MEK by U0126 mimic the AR149 overexpression phenotype, supporting a role of ARAF regulated ERK signalling at endosomes that is controlled by AR149 and targets ARF6. Our data additionally suggest EFA6 as a partner of A-RAF during activation of ARF6. The novel findings on the A-RAF localization and the interaction with ARF6 have led to a new model of ARAF function were A-RAF via activation of ARF6 controls the recycling of endocytic vesicles.Endocytosis and rapid recycling of synaptic vesicles is critically important for the physiological function of neurons. The finding, that A-RAF regulates endocytic recycling open a new perspective for investigation of the role of A-RAF in the nervous system.